doi: 10.1200/JCO.2007.12.0758.
Epub 2007 Jul 16.
The value meal: how to save $1,700 per month or more on lapatinib
Affiliations
- PMID: 17635950
- DOI: 10.1200/JCO.2007.12.0758
Item in Clipboard
The value meal: how to save $1,700 per month or more on lapatinib
J Clin Oncol.
.
No abstract available
Comment in
-
The value of label recommendations: how to dose lapatinib.J Clin Oncol. 2007 Nov 20;25(33):5331-2; author reply 5334-5. doi: 10.1200/JCO.2007.13.8644. J Clin Oncol. 2007. PMID: 18024883 No abstract available.
-
Effect of food on lapatinib pharmacokinetics.J Clin Oncol. 2007 Nov 20;25(33):5332-3; author reply 5334-5. doi: 10.1200/JCO.2007.13.9345. J Clin Oncol. 2007. PMID: 18024884 No abstract available.
-
The value meal: effect of food on lapatinib bioavailability.J Clin Oncol. 2007 Nov 20;25(33):5333-4; author reply 5334-5. doi: 10.1200/JCO.2007.14.6381. J Clin Oncol. 2007. PMID: 18024885 No abstract available.
-
Controversies in using lapatinib at reduced dosage with food.J Clin Oncol. 2007 Nov 20;25(33):5333; author reply 5334-5. doi: 10.1200/JCO.2007.13.9501. J Clin Oncol. 2007. PMID: 18024886 No abstract available.
Similar articles
-
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Clin Ther. 2008. PMID: 18803986 Review.
-
The value of label recommendations: how to dose lapatinib.J Clin Oncol. 2007 Nov 20;25(33):5331-2; author reply 5334-5. doi: 10.1200/JCO.2007.13.8644. J Clin Oncol. 2007. PMID: 18024883 No abstract available.
-
[Oral drug administration].Med Clin (Barc). 1997 Mar 22;108(11):426-35. Med Clin (Barc). 1997. PMID: 9213642 Review. Spanish. No abstract available.
-
Lapatinib and ixabepilone for the treatment of metastatic breast cancer.Pharmacotherapy. 2008 Oct;28(10):1255-66. doi: 10.1592/phco.28.10.1255. Pharmacotherapy. 2008. PMID: 18823221 Review.
-
Rotarix packaging: labelling and packaging change. More improvement needed. Confusing oral syringe still available.Prescrire Int. 2008 Oct;17(97):196. Prescrire Int. 2008. PMID: 19537308 No abstract available.
Cited by
-
Formulation of Lipid-Based Nanoparticles for Simultaneous Delivery of Lapatinib and Anti-Survivin siRNA for HER2+ Breast Cancer Treatment.Pharmaceuticals (Basel). 2022 Nov 23;15(12):1452. doi: 10.3390/ph15121452. Pharmaceuticals (Basel). 2022. PMID: 36558904 Free PMC article.
-
Could African and Low- and Middle-Income Countries Contribute Scientifically to Global Cancer Care?J Glob Oncol. 2015 Nov 12;1(2):49-53. doi: 10.1200/JGO.2015.001032. eCollection 2015 Dec. J Glob Oncol. 2015. PMID: 28804772 Free PMC article. No abstract available.
-
Metabolism considerations for kinase inhibitors in cancer treatment.Expert Opin Drug Metab Toxicol. 2010 Oct;6(10):1175-93. doi: 10.1517/17425255.2010.506873. Expert Opin Drug Metab Toxicol. 2010. PMID: 20684746 Free PMC article. Review.
-
Her2 positive metastatic breast cancer treated with low dose lapatinib in a resource-constrained setting in South India: a retrospective audit.Ecancermedicalscience. 2024 Sep 6;18:1758. doi: 10.3332/ecancer.2024.1758. eCollection 2024. Ecancermedicalscience. 2024. PMID: 39430084 Free PMC article.
-
Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design.Mol Oncol. 2012 Apr;6(2):196-203. doi: 10.1016/j.molonc.2012.01.009. Epub 2012 Feb 16. Mol Oncol. 2012. PMID: 22386481 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
